Eloralintide
Amylin · s.c. · Eli Lilly
Summary
- Also known as
- LY3841136
- Mechanism
- Amylin
- Route
- s.c.
- Company
- Eli Lilly
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 ENLIGHTEN programme recruiting since Dec 2025 (obesity, T2D, sleep apnoea, knee osteoarthritis, maintenance after incretin therapy); phase 2 complete verify
- Next milestone
- ENLIGHTEN phase 3 results
Sources for the status
- Eli Lilly and Company. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes (ENLIGHTEN-1). ClinicalTrials.gov identifier NCT07321886. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07321886
- Eli Lilly and Company. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2). ClinicalTrials.gov identifier NCT07282600. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07282600
- Billings LK, Hsia S, Bays H, Tidemann-Miller B, O'Hagan J, Tham LS, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10520):2631-2643. PMID: 41207310.
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | Phase 3 ongoing | |
| T2D | 2 phase 3 ongoing | Phase 3 ongoing | |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 2 phase 3 ongoing | Phase 3 ongoing | |
| Knee OA | 2 phase 3 ongoing | Phase 3 ongoing | |
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EloraTZP phase 2b (obesity + T2D) | eloralintide 3 mg | t2d | 48 | — | −8.2 % vs −3.0 % Δ −5.2 pp | — | −1.1 vs −0.3 | — | — | — | — | — | — | press release |
| EloraTZP phase 2b (obesity + T2D) | eloralintide 6 mg | t2d | 48 | — | −12.3 % vs −3.0 % Δ −9.3 pp | — | −1.4 vs −0.3 | — | — | — | — | — | — | press release |
| EloraTZP phase 2b (obesity + T2D) | eloralintide 9 mg | t2d | 48 | — | −11.1 % vs −3.0 % Δ −8.1 pp | — | −1.3 vs −0.3 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (3)
- eloralintide 3 mg · weight_eff · press release table
Elora 3 mg -8.2 %
- eloralintide 6 mg · weight_eff · press release table
Elora 6 mg -12.3 %
- eloralintide 9 mg · weight_eff · press release table
Elora 9 mg -11.1 %
Registered trials (6)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| ENLIGHTEN-10 A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Obesity | Phase 3 | not yet recruiting | 2026-12 → 2029-11 | 3000 | not yet recruiting | NCT07900633 |
| ENLIGHTEN-1 A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Obesity | Phase 3 | recruiting | 2026-02 → 2028-03 | 1980 | recruiting | NCT07321886 |
| ENLIGHTEN-4 Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight | Knee OA | Phase 3 | recruiting | 2026-02 → 2028-03 | 900 | recruiting | NCT07353931 |
| ENLIGHTEN-3 A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight | Sleep apnoea | Phase 3 | recruiting | 2026-02 → 2028-03 | 800 | recruiting | NCT07369011 |
| ENLIGHTEN-6 A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Obesity | Phase 3 | recruiting | 2026-02 → 2028-06 | 900 | recruiting | NCT07392190 |
| ENLIGHTEN-2 A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Obesity | Phase 3 | recruiting | 2025-12 → 2028-01 | 1035 | recruiting | NCT07282600 |
Primary sources
How to cite this page
Cite the primary publication for any single result; every value above links to it.